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RNA and protein stabilization
Ras/MAPK-pathway
ERM proteins
Agar colony formationa b s t r a c t
The cell surface glycoprotein CD44 enhances phorbol-12-myristate 13-acetate (TPA)-induced expres-
sion of p21WAF1 by stabilizing its mRNA and enhancing the protein’s half-life in several cell lines.
Only the plasma membrane-anchored cytoplasmic tail of CD44 and its interacting ezrin, radixin,
moesin (ERM) proteins are required for this effect. A mitogen activated kinase (MEK) inhibitor abol-
ishes the action of CD44 on p21. Down-regulation of p21 dramatically decreased anchorage-inde-
pendence of a cancer cell line, whereas CD44 expression in this background could partially rescue
the phenotype.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The transmembrane glycoprotein CD44 has been identiﬁed as a
marker protein for human and murine cancer-initiating cells [1–6]
and normal stem cells [7]. In tumor-prone ApcMin/+ mice CD44
stimulates the generation of polyp formation [8]. In addition to this
role early in cancer initiation, CD44 promotes proliferation and
cancer cell metastasis [9–11]. It is upregulated in numerous human
and rodent cancers [12–17]. CD44 occurs in several alternative
splice forms some of which have been shown to act as co-receptors
for receptor tyrosine kinases and to promote through interaction
with ezrin, radixin, moesin (ERM) proteins the activation of Ras
[18–21]. To counteract the growth promoting action of CD44, the
tumor suppressor p53 downregulates CD44 transcription [22].
And the reverse, CD44 inhibits p53 expression [22]. We therefore
expected that CD44 in its growth promoting function needs toeliminate cell cycle repressors, e.g. the p53 dependent synthesis
of p21WAF which inhibits Cdks [23,24]. We report here the surpris-
ing ﬁnding that CD44 upregulates p21 levels and that p21 is re-
quired for agar colony growth of a tumor cell lines.
2. Materials and methods
2.1. Reagents
Antibodies from Santa Cruz Biotechnology Inc. (Santa Cruz, CA,
USA): HCAM F-4 (sc-9960), Actin I-19 (sc-1616), c-Myc 9E10 (sc-
40), p21 C-19 (sc-397), ERM H-300 (sc-32918) and HA-probe F-7
(sc-7392). Sigma–Aldrich (St. Louis, USA): monoclonal Flag-Anti-
body (F3165), phorbol-12-myristate 13-acetate (TPA), actinomycin
D and cycloheximide (CHX). BD Bioscience (NJ, USA): Anti murine
CD44 antibody (clone IM7, 553131). Thermo Scientiﬁc Dharmacon
(Rockford, IL, USA): siRNA,s against human ezrin (GeneID 7430),
human moesin (GeneID 4478) and human radixin (GeneID 5962)
and Non-TARGETplusTM Pool (served as control). Sigma–Aldrich
(St. Louis, MO, USA): shRNA against p21 (clone 1–5) (GeneID
1026). Life Technologies (CA, USA): siRNA against murine CD44
(Ambion, ID: s63661). Enzo Life Sciences GmbH (Lörrach, Ger-
many): c-secretase inhibitor DAPT. Cell Signaling Technology
(Danvers, MA, USA): MEK1/2 inhibitor UO126.
Table 1




CD44DE KKK-AAA fwd gaagaaggtgtgggcaggcggcagcgctagtgatcaacag
CD44DE KKK-AAA rev clgttgatcactagcgctgccgcclgcccacaccttcttc
CD44DE RR-AA fwd ttgcagtcaacagtcgagcagcgtgtgggcaggcggcag
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The CD44-negative human melanoma cell line RPM-MC and
NIH3T3 cell line were grown at low cell density (3  105 cells/
6 cm plate) in Dulbecco’s modiﬁed Eagle’s medium (DMEM, PAA
Laboratories GmbH, Pasching, Austria) supplemented with 10% fe-
tal bovine serum (PAA Laboratories GmbH, Pasching, Austria) in a
humidiﬁed 5% (v/v) atmosphere of CO2 at 37 C.
2.3. Plasmids and transfection of cells
A rat CD44, doubly-tagged with both an N-terminal FLAG
epitope and a C-terminal myc epitope, was used. Brieﬂy, a PCR
product was subcloned into the NotI/XbaI sites of pFLAG-
myc-CMV™-21 expression vector (Sigma–Aldrich, St. Louis, MO,
USA). The CD44KRmutant (mutation of ERM binding site) was gen-Fig. 1. CD44 expression increases the TPA-induced p21 level. Activation of the Ras/MA
transiently transfected with CD44 or a control vector for 14 h. Cells were treated with T
mRNA analyzed by qRT-PCR (B). (C) NIH3T3 cells were transfected with siRNA against
activation (10 lM UO126). Cells were infected with lentiviral particles expressing CD44
(100 ng/ml) and cells were harvested after 20 h. Analysis of samples as in (A).erated by site-directed mutagenesis using the following primers:
fwd CD44KR and rev CD44KR. The CD44DE (deletion of the
extracellular part) was kindly provided by Christoph Kaether (FLI
Jena, Germany) [25]. Its corresponding ERM binding mutants
(CD44DEKR and CD44DEKK) were generated by site directed
mutagenesis, using the following primers: CD44DE KKK-AAA fwd
and CD44DE KKK-AAA rev or CD44DE RR-AA fwd and
CD44DE RR-AA rev. The CD44DICD (deletion of intracellular do-
main (ICD), aa 290–360) was generated using the CD44DICD fwd
and rev oligonucleotides. The human CD44ICD was subcloned into
the pcDNA3.1hygro + vector (Invitrogen GmbH, Darmstadt,
Germany) using the CD44ICD fwd and rev primers. The dominant
negative human Myc-tagged ezrin R579A has been described
[19]. Human CD44 was subcloned into the lentiviral pCDH-CuO-
MCS-EF1-copGFP vector using the CD44Cumate fwd and rev
primer.
A p21-promoter fused to ﬁreﬂy luciferase was purchased from
addgene (plasmid 16462) [26]. A dominant positive Ras Q61L
(HA-tagged) was cloned into a pcDNA3.1 vector (Invitrogen GmbH,
Darmstadt, Germany) using the Ras Q61L Fwd primer and the Ras
Q61L Rev primer. All cloning primers used in this work are listed in
Table 1.
Cells were transfected with Lipofectamine 2000 (Invitrogen
GmbH, Darmstadt, Germany).
For lentiviral transductions HEK293 cells were transiently
transfected with the plasmid of interest together with a packaging
and an envelope plasmid using Lipofectamine 2000 (Invitrogen
GmbH, Darmstadt, Germany) according to the manufacturer’s
instructions. The viral particles were harvested 48 h later and ﬁl-
tered through 0.22 lm pore cellulose acetate ﬁlters. Filtered super-
natants were used for infection experiments.PK pathway is obligatory to mediate p21 induction. (A and B) RPM-MC cells were
PA (100 ng/ml) and harvested at 20 h for Western blotting (A) and at 12 h for p21
CD44 or a scrambled control for 48 h and treated as in (A). (D) Inhibition of MEK
or a control vector. UO126 was added to the indicated samples together with TPA
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To induce p21WAF1 expression, cells were treated with 100 ng/
ml of TPA. c-Secretase activity was blocked by 5 lM DAPT over-
night, MEK1/2 activity by 10 lM UO126 added at the same time
with TPA. Protein synthesis was inhibited by 25 lg/ml CHX. Cells
were treated with 2 lg/ml actinomycin D to determine the half-life
of p21 mRNA [27].
2.5. Western blotting and reporter assays
Cells were harvested in 250 ll 2  Laemmli sample buffer and
the by safe heated to 96 C for 5 min. The proteins were resolved
on SDS–PAGE and transferred to a nitrocellulose membrane
(0.2 lm pore size, Carl Roth, Karlsruhe, Germany) using a wet-
transfer method. Antigens 006Fn the membranes were detected
by antibodies followed by the appropriate HRP-conjugated second-
ary antibody, and visualized by incubation with Pierce ECL Wes-
tern blotting substrate (Thermo Scientiﬁc, Rockford, IL, USA).
For luciferase reporter assays, cells were cultured in 24-well
plates and analyzed using the luciferase assay system of Promega
(Madison, WI, USA). Western blots were quantiﬁed using image j.
Fold inductions were calculated using actin bands as reference.
2.6. RNA isolation and quantitative real-time PCR (qRT-PCR)
RNAwas isolated using the RneasyMini Kit (Qiagen, Hilden, Ger-
many). Subsequently 1 lg of total RNAwas reverse transcribedwith
oligo dT primers and 200 U of Superscript (Invitrogen GmbH,
Darmstadt, Germany). cDNA was analyzed by qPCR (Sybr Green
Invitrogen™) using the following primers: actin fwd 50AGAGGGAFig. 2. Analysis of CD44 mutants: deletion of the intracellular domain (ICD) abolished
representation of CD44 proteins used in this study is shown. Cells were transiently transfe
for 14 h. Procedures as in Fig. 1A. Note that the CD44DICD has a strong tendency to dime
PAGE. Since there is no working antibody available, expression of the CD44ICD mRNA
shown).AATCGTGCGTGAC30 and actin rev 50CAATAGTGATGACCTGGCCGT30;
human p21-RTF1 50TGCCGAAGTCAGTTCCTTGTGG30 and human
p21-RTR1 50CGCATGGGTTCTGACGGACATCC30. The qPCR results
were standardized ﬁrst to actin, and subsequently to non-treated
cellular controls.
2.7. Scratch wound assay
Scratch-wound assays were performed in 6-well plates at high
cell density (3.5  105 cells/well). The day after seeding, cells were
starved in 0.5% FCS for 24 h. Scratches were introduced with a
200 ll pipette tip. Cells were treated +/ 100 ng/ml TPA. Scratches
were photographed over time. The areas of the scratches were cal-
culated using photoshop and image j. Assays were performed in
triplicates.
2.8. Soft-agar-assay
Soft agar assays were performed in 24-well plates. Approxi-
mately 350 cells were seeded in 0.33% agar–agar (Roth) per well
in triplicates. Number of colonies was counted after 9 days.
2.9. Statistical analysis
Statistical signiﬁcance was determined using Student’s t-test.
The data are expressed as the means ± SEM. A P value less than
0.05 was considered statistically signiﬁcant. All our experiments
were repeated at least three times and each experiment has triple
wells. In indicated cases one representative experiment was se-
lected to draw diagrams and data analysis.increase of p21. Soluble ICD alone could not restore p21 regulation. A schematic
cted with a control vector, CD44Wt, CD44KR-Mt, CD44DICD or the soluble CD44ICD
rize which in this experiment was not completely eliminated by treatment for SDS–
was evaluated by qRT-PCR and found to be similar to that of CD44Wt mRNA (not
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The unexpected result that CD44 does not reduce but rather en-
hances p21 levels, was observed in several cell lines. Fig. 1A exem-
pliﬁes this ﬁnding. CD44 (the most abundant standard isoform
[28]) transfected into a CD44-negative cell line, the human mela-
noma tumor cell line RPM-MC, enhanced the phorbol ester induced
expression of p21 protein about two to three fold (Fig. 1A). Also the
p21 mRNA levels were elevated by the presence of CD44, also
about two to three fold (Fig. 1B). Downregulation of CD44 synthe-
sis in NIH3T3 cells reduced phorbol ester induced p21 expression,
whereas in control cells TPA treatment induced p21 (Fig. 1C). The
enhancement was independent of p53 (not shown), but rather de-
pended on activation of the Ras/MAPK pathway. The mitogen acti-
vated kinase (MEK) activation inhibitor UO126 blocked theFig. 3. Analysis of CD44 mutants: The CD44ICD needs to be anchored to the plasma mem
(A) RPM-MC cells were transiently transfected with CD44Wt, CD44DICD, soluble CD44IC
same extend as CD44Wt. (B) Cells were transiently transfected with a control vector or C
analyzed as in 1B. (C) Analysis of CD44DE mutants lacking the ERM binding site. The CD44
transiently transfected for 14 h. Treatments and analysis as in Fig. 1A. (D) RPM-MC cells
moesin or with a scrambled control for 24 h (transfection efﬁciency was 85%). Afterward
Fig. 1A. (E) RPM-MC cells were infected with lentiviral particles expressing CD44. CD44 p
transfected with a control vector or a dominant negative ezrin (ezR579A), which cannoinduction of p21 by phorbol ester and the enhancement by CD44
(Fig. 1D).
We ask three questions: (i) which domain of CD44 is responsi-
ble for the effect on p21? (ii) On which level is p21 expression reg-
ulated (transcription, translation or posttranslational)? (iii) What
is the cellular phenotypic consequence of the enhanced p21 levels?
To identify the CD44 domain relevant for the p21 induction, we
transfected several mutant constructs into the CD44 negative RPM-
MC cells. Deletion of the cytoplasmic tail (CD44DICD, Fig. 2, com-
pare lanes 7 and 8 with lanes 3 and 4 and Fig. 3A) eliminated the
enhancement of p21. Expressing only the ICD as a soluble peptide
did not restore the enhancement, but did not affect the induction
by TPA (CD44ICD, Fig. 2, lanes 9 and 10 and CD44 Tail in Fig. 3A).
Interestingly, the ectodomain of CD44 could be deleted without
affecting p21 induction (CD44DE in Fig. 3A and C, lanes 3 and 4).brane (CD44DE) where it interacts with ERM proteins to mediate the p21 increase.
D or CD44DE for 14 h. Procedures as in Fig. 1B. CD44DE increases p21 RNA level to a
D44 for 14 h and pre-incubated with the c-secretase inhibitor DAPT (5 lM) O/N and
DE and two ERM binding motif mutants (CD44DE KR-Mt and CD44DE KK-Mt) were
were transfected with equal amounts of siRNA’s against human ezrin radixin and
s cells were transfected with CD44 or a control vector for 14 h and processed as in
ositive cells were selected by FACS sorting. Subsequently the cells were transiently
t activate the Ras/MAPK pathway. Processing and analysis as in Fig. 1A.
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ﬁced to induce p21. CD44 is subject to ADAM10 and subsequent c-
secretase dependent processing [29] which releases the ICD for nu-
clear uptake. Because the soluble ICD could not regulate p21, inhi-
bition of CD44 cleavage should not inhibit p21 induction. This is
the case: a c-secretase inhibitor (DAPT) did not affect the enhance-
ment of p21 RNA (Fig. 3B). The membrane-attached ICD is the
docking site for ERM proteins [30–32]. ERM proteins are required
for the activation of Ras [18–21]. Could ERM proteins be interme-
diates in the induction of p21 via the Ras/MAPK pathway? Muta-
tion of the ERM binding site either in the full-length CD44
molecule (CD44KR-Mt; Fig. 2, lanes 5 and 6) or in the truncated
CD44DE (Fig. 3C, lanes 5–8) indeed affected the induction. Accord-
ingly, siRNA dependent downregulation of ERM proteins prevented
the enhancement by CD44 (Fig. 3D). ERM proteins can be seques-
tered from a membrane proximal position by overexpressing the
CD44ICD [33]. In Fig. 2, the ICD was overexpressed in the absence
of CD44. Its ability to sequester ERM proteins does expectedly not
affect the p21 induction by TPA. The members of the ERM family
are structurally similar and substitute for each other, at least for
all functions tested so far [34]. Because ERM proteins are abundant
and activated by phosphorylation in many proliferating cells
including RPM-MC cells [35,36], overexpression of one of them, ez-
rin, did not further enhance p21 expression (transfected ezrin is
also phosphorylated [20]; not shown). The function of the endoge-
nous ERM proteins could however be inhibited by overexpressing
dominant negative mutants of ezrin. An example is shown in
Fig. 3E: ezrinR579A which inhibits Ras activation, totally blocks
p21 enhancement. We conclude that the membrane-anchoredFig. 4. CD44 enhances both p21 RNA and protein half life, but does not inﬂuence p21 pro
vector or CD44 together with a p21-promoter construct fused to Fireﬂy-Luciferase. After o
after addition of Fireﬂy-luciferase substrate. (B) Cells were transfected with a control vect
ml) was added to the cells and samples were harvested at indicated time points. p21 mR
addition of actinomycin D). (C) Cells were transfected with a control vector or CD44 for 14
and samples were harvested at indicated time points. p21 protein levels determined byCD44 tail through ERM proteins stimulates the Ras/MAPK pathway
through which p21 is increased.
To now study through which step p21 is enhanced, we ﬁrst con-
centrated on the p21 promoter. Expression from p21 promoter re-
porter constructs was not enhanced by the presence of CD44
(Fig. 4A). Transcription was apparently not inﬂuenced by CD44.
Blocking experiments with actinomycin D and cycloheximid
showed that CD44 rather prolonged the half-life of p21 RNA
(Fig. 4B), a novel ﬁnding, and the life time of p21 protein (Fig. 4C).
How does the moderate increase in p21 levels affect cellular
behavior? We examined three cellular parameters: proliferation,
migration and anchorage independent growth; and compared
RPM-MC cells without CD44 and with CD44 expression, and down-
regulated p21 by lentivirally introduced shRNA in both conditions.
Proliferation rate was not signiﬁcantly altered in CD44 positive
cells, but strongly decreased in p21 knockdown (KD) cells (not
shown). Healing of scratch wounds was enhanced by TPA treat-
ment, but not affected by p21 downregulation (Fig. 5A). Presence
or absence of CD44 made no difference (not shown). As tumor cells
the RPM-MC cells form colonies in soft agar. Introduction of CD44
slightly increase colony counts, not signiﬁcant statistically
(Fig. 5B). p21 knockdown however drastically reduced the ability
of cells to grow in soft agar (Fig. 5B). Expectedly, expression of
CD44 in the p21 knockdown background partially rescued anchor-
age-independence indicating that the CD44-ezrin pathway, in
addition to enhancing p21 levels, promoted proliferation through
its action on Ras. There was a signiﬁcant difference in colony size:
in the control cells with p21 knockdown the colonies were very
small compared to control and CD44 expressing cells (not shown).moter activity. (A) RPM-MC cells were transiently transfected with either a control
vernight treatment with TPA, cells were harvested and luminescence was measured
or or CD44 for 14 h, then treated with TPA for 12 h. Afterwards actinomycin D (2 lg/
NA levels determined by qRT-PCR, were plotted relative to that at time zero (before
h, then treated with TPA for 20 h. Afterwards CHX (25 lg/ml) was added to the cells
Western blot, were plotted relative to that at time zero (before addition of CHX).
Fig. 5. p21 is required for anchorage independent growth, but not for migration. (A)
Wound healing experiment: RPM-MC cells were infected with a lentiviral control
vector or a vector expressing shRNA against p21 (clone 4). Transduced cells were
selected with puromycin. Closing of scratches was observed +/ TPA (100 ng/ml).
(B) RPM-MC cells were infected with lentiviral particles expressing CD44 or a
control vector, and selected by FACS. Subsequently, p21 was downregulated and
selected as in (A). The cells were tested for anchorage-independent growth by their
colony forming ability in soft agar.
Fig. 6. Schematic representation of CD44 action. The membrane-bound CD44ICD
(CD44DE) sufﬁces to interact with ERM proteins and thereby to activate the Ras–
MEK–Erk pathway. Through this pathway CD44 colaborates with TPA in the action
on p21.
C. Lindner et al. / FEBS Letters 587 (2013) 2698–2704 2703CD44 expression in the p21 knockdown background fully rescued
size of colonies.
4. Discussion
Phorbol ester treatment induces p21WAF1 in different cell types
[37–39]. We show here that CD44 enhances the phorbol ester in-
duced expression of p21 by prolonging both the life time of its
mRNA and of p21 protein. The effect on p21 is mediated through
the Ras–MEK–Erk pathway which requires the action of ERM pro-
teins bound to CD44 (Fig. 6). ERM proteins are required for the acti-
vation of Ras and Rac [19,21]. An increase in p21 protein stability
in Ras-transformed ﬁbroblasts has been reported previously [40].
The effect on mRNA life time is a novel observation. CD44 and par-
ticularly its longer splice variants have been shown to act as co-
receptors for receptor tyrosine kinases [18,21]. The co-receptor ac-
tion depends on the extracellular domain of CD44 that mediates a
local enrichment of the receptor ligands. It is surprising that the
function of CD44 described here does not require the extracellular
domain. CD44 cleavage by metalloproteases and subsequently by
c-secretase is also not involved. Rather simply the interaction with
ERM proteins catalyzes the enhancement of p21. Apparently and to
our surprise, there is no other ERM anchor available in cells with
respect to the Ras-activating function of the ERM proteins, at least
in the cell lines used here, RPM-MC and NIH3T3. This might be in
contrast to other roles of ERM, e.g. in cell motility, protrusion for-
mation and migration [41–44].
The presence of p21 and of its increased levels in response to
CD44 participate in the ability of cells to grow under anchorage-
independent conditions. Thus, CD44 and p21 co-operated in pro-
moting tumor formation. Indications for this role of p21 have been
reported previously [45]. While the action of p21WAF1 as a cell cycle
regulator inhibiting Cdks [23,24] suggests that p21 may serve as a
tumor suppressor [46], a tumor-promoting function has been sug-
gested by a number of observations [47–49], nicely compiled in an
editorial [50] and review [51]. For instance, elimination of p21 in
p53-deﬁcient mice resulted in a signiﬁcant extension of life-span,
apparently due to a decrease in the rate of spontaneous thymic
lymphomas [47]. In cell culture p21WAF1 is required for the com-
plete oncogenic transformation of murine embryonic ﬁbroblasts
[52], and for anchorage-independence of a colon carcinoma cell
line (HCT116) [45]. The big ‘‘unknown’’ to be resolved is, what con-
verts p21 function from inhibiting the cell cycle to supporting tu-
mor growth.
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